Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Can the gene and cell therapy revolution scale up?

A manufacturing capacity crunch is causing headaches for the burgeoning cell and gene therapy market. Smaller drug development firms will rely on contract manufacturing organisations to produce the viral vectors necessary to move towards commercialisation, but wait times to start cell/gene therapy projects are reportedly now around 16 months. What’s the reason for the backlog, and what are manufacturers doing to clear it?


Go Top